Merus (NASDAQ:MRUS) VP Sells $163,370.00 in Stock

Merus N.V. (NASDAQ:MRUS) VP Harry Shuman sold 1,700 shares of Merus stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $96.10, for a total transaction of $163,370.00. Following the completion of the transaction, the vice president directly owned 11,002 shares of the company’s stock, valued at $1,057,292.20. This trade represents a 13.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Harry Shuman also recently made the following trade(s):

• On Tuesday, November 25th, Harry Shuman sold 8,300 shares of Merus stock. The stock was sold at an average price of $95.92, for a total transaction of $796,136.00.

Merus Trading Up 0.4%

NASDAQ MRUS traded up $0.41 during trading hours on Wednesday, reaching $96.77. The company’s stock had a trading volume of 3,132,743 shares, compared to its average volume of 1,281,310. The business has a 50-day simple moving average of $95.26 and a 200 day simple moving average of $73.73. Merus N.V. has a 52 week low of $33.19 and a 52 week high of $96.83. The stock has a market cap of $7.34 billion, a PE ratio of -18.26 and a beta of 1.06.

Analysts Set New Price Targets

A number of research analysts recently issued reports on MRUS shares. Needham & Company LLC lowered Merus from a “buy” rating to a “hold” rating and set a $96.00 price objective for the company. in a research report on Monday, September 29th. Industrial Alliance Securities set a $90.00 price target on shares of Merus in a report on Monday, August 25th. William Blair lowered shares of Merus from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Merus in a research report on Wednesday, October 8th. Finally, HC Wainwright cut shares of Merus from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $135.00 to $97.00 in a research report on Monday, September 29th. Three investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $93.56.

Institutional Investors Weigh In On Merus

Several institutional investors have recently bought and sold shares of MRUS. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Merus by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock worth $141,000 after buying an additional 362 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Merus by 66.7% in the second quarter. Allianz Asset Management GmbH now owns 26,000 shares of the biotechnology company’s stock valued at $1,368,000 after buying an additional 10,400 shares in the last quarter. Atle Fund Management AB lifted its position in shares of Merus by 69.7% during the 2nd quarter. Atle Fund Management AB now owns 59,889 shares of the biotechnology company’s stock valued at $3,150,000 after acquiring an additional 24,597 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of Merus by 26.3% during the 1st quarter. Voya Investment Management LLC now owns 78,280 shares of the biotechnology company’s stock worth $3,295,000 after acquiring an additional 16,280 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Merus by 324.1% in the 1st quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 2,243 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.